Valuation: Revolution Medicines, Inc.

Capitalization 7.8B 7.54B 7.09B 6.29B 11.16B 684B 12.45B 85.24B 31.67B 281B 29.23B 28.64B 1,179B P/E ratio 2024 *
-12.1x
P/E ratio 2025 * -10.5x
Enterprise value 6.01B 5.81B 5.46B 4.85B 8.61B 527B 9.6B 65.71B 24.42B 216B 22.53B 22.08B 909B EV / Sales 2024 *
17,363x
EV / Sales 2025 * 4,801x
Free-Float
86.7%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-3.17%
1 week-1.77%
Current month-1.77%
1 month-5.02%
3 months-30.20%
6 months-1.66%
Current year-3.54%
More quotes
1 week
41.76
Extreme 41.76
44.68
1 month
39.36
Extreme 39.36
44.68
Current year
39.36
Extreme 39.36
45.25
1 year
28.43
Extreme 28.43
62.40
3 years
14.08
Extreme 14.08
62.40
5 years
14.08
Extreme 14.08
62.40
10 years
14.08
Extreme 14.08
62.40
More quotes
Director TitleAgeSince
Chief Executive Officer 63 2014-10-31
Director of Finance/CFO 48 2018-09-30
Chief Tech/Sci/R&D Officer 64 2023-03-31
Manager TitleAgeSince
Chairman 63 -
Director/Board Member 67 2015-02-28
Director/Board Member 53 2014-10-31
More insiders
Add to a list
Change 5d. change 1-year change 3-years change Capi.($)
-3.17%-1.77%+38.60%+87.10% 7.8B
-1.50%+3.75%+35.87%-3.30% 47.96B
-0.87%+3.37%-4.61%-18.56% 36.65B
-0.77%-0.06%+5.00%+22.20% 26.22B
-1.27%-2.82%-30.53%-30.59% 15.97B
-1.71%-0.99%+63.75%+69.66% 15.52B
-3.01%-17.30%-62.70%-80.13% 12.55B
-2.93%-1.01%+7.15%-31.33% 11.51B
-1.90%+1.42%+8.49%+98.15% 10.98B
+6.11%+20.16% - - 10.86B
Average -1.10%+0.69%+6.78%+12.58% 19.6B
Weighted average by Cap. -1.13%+1.47%+10.12%+3.93%
See all sector performances

Financials

2024 *2025 *
Net sales 346K 335K 315K 279K 496K 30.35M 553K 3.78M 1.41M 12.45M 1.3M 1.27M 52.34M 1.38M 1.34M 1.26M 1.12M 1.98M 121M 2.21M 15.14M 5.62M 49.82M 5.19M 5.09M 209M
Net income -581M -562M -528M -469M -832M -50.97B -928M -6.35B -2.36B -20.91B -2.18B -2.13B -87.88B -711M -688M -646M -573M -1.02B -62.34B -1.14B -7.77B -2.89B -25.58B -2.67B -2.61B -108B
Net Debt -1.79B -1.73B -1.62B -1.44B -2.56B -157B -2.85B -19.53B -7.26B -64.26B -6.7B -6.56B -270B -1.15B -1.11B -1.04B -926M -1.64B -101B -1.83B -12.56B -4.67B -41.32B -4.31B -4.22B -174B
More financial data * Estimated data
Logo Revolution Medicines, Inc.
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
Employees
490
More about the company
Date Price Change Volume
25-02-07 42.19 $ -3.17% 999,674
25-02-06 43.57 $ -1.54% 1,795,601
25-02-05 44.25 $ +4.56% 1,494,147
25-02-04 42.32 $ +0.43% 844,413
25-02-03 42.14 $ -1.89% 897,150

Delayed Quote Nasdaq, February 07, 2025 at 04:00 pm

More quotes
Trading Rating
Investor Rating
ESG MSCI
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
42.19USD
Average target price
73.29USD
Spread / Average Target
+73.70%
Consensus

Quarterly revenue - Rate of surprise